RECRUITINGEarly Phase 1INTERVENTIONAL
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
An Open-label, Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intraocular Administration of FT-002 in Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa.
About This Trial
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Who May Be Eligible (Plain English)
Who May Qualify:
1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the willing to sign a consent form Form; 4.Subjects who are confirmed with variants of RPGR ;
Who Should NOT Join This Trial:
1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ;
Exclusion Criteria:
1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.
Treatments Being Tested
GENETIC
FT-002
Comparison of different dosages of FT-002
Locations (2)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Eye & ENT hospital of Fudan university
Shanghai, Shanghai Municipality, China